CLAIMS

1- Use of a chemical compounds for the preparation of a pharmaceutical composition to attenuate or to inhibit Dengue virus infection, wherein such said chemical compounds is selected from the group consisting of C-SIJ01002, C-SIJ01003, C-SIJ01006, C-SIJ01008, C-SIJ01009, C-SIJ01020, C-SIJ01023, C-SIJ01026, C-SIJ01031, C-SIJ01033, C-SIJ01062, C-SIJ06102, C-SIJ06111, C-SIJ01034, C-SIJ01039, C-SIJ01042, C-SJI01045, C-SIJ01047, C-SIJ01051, C-SIJ01056, C-SIJ01066, C-SIJ04078, C-SIJ06097, C-SIJ06099, C-SIJ06103, and C-SIJ12143 as listed in Table 3comprise the following substructure:.

[C]-[A]

Where,

[A] is defined as **anchor** and corresponds to a chemical substructure capable to bind to the **cleft associated to "ij" loop** in E protein defined in the present invention, and such **anchor** substructure corresponds to any of the following radicals: A-SIJ001, A-SIJ002, A-SIJ006, A-SIJ011, A-SIJ015, A-SIJ016, A-SIJ020, A-SIJ021, A-SIJ022, A-SIJ023, A-SIJ028, A-SIJ030, A-SIJ044, A-SIJ052, A-SIJ053, A-SIJ072, A-SIJ078, A-SIJ085, A-SIJ086, A-SIJ111, A-SIJ115, A-SIJ118, A-SIJ116, A-SIJ117, A-SIJ121, A-SIJ122, A-SIJ123, A-SIJ124, A-SIJ125, A-SIJ126, A-SIJ127, A-SIJ128, A-SIJ130, A-SIJ131, A-SIJ132, A-SIJ133, A-SIJ134, A-SIJ135, A-SIJ136, A-SIJ137, A-SIJ138, A-SIJ140, A-SIJ141, A-SIJ142, A-SIJ144, A-SIJ145, A-SIJ146, A-SIJ147, A-SIJ149, A-SIJ150, A-SIJ151, A-SIJ152, A-SIJ153, A-SIJ154, A-SIJ155, A-SIJ156, A-SIJ157, A-SIJ158, A-SIJ160, A-SIJ161, A-SIJ162, A-SIJ163, A-SIJ164, A-SIJ165, A-SIJ166, A-SIJ167, A-SIJ168, A-SIJ169, A-SIJ170, A-SIJ171, A-SIJ172, A-SIJ173, A-SIJ174, A-SIJ179, A-SIJ180, A-SIJ181, A-SIJ182, A-SIJ183, A-SIJ184, A-SIJ185, A-SIJ186 and A-SIJ188.

[C] is defined as **head** and corresponds to a chemical substructure covalently attached to the **anchor** substructure **[A]** and such substructure offers or favors the capacity of the molecules described in the present invention to inhibit Dengue virus infection affecting or modulating one or more of the intermolecular interactions in which E protein is involved, wherein **[C]** is selected from any one of the following group:

(i) **[C]** corresponds to a hydrogen atom,

(ii) **[C]** corresponds to any of the following chemical substructures: a) alkyl radical C1-C10 or heteroalkyl radical C1-C10 with no more than three heteroatoms optionally substituted or not substituted; b) cycloalkyl or heterocycloalkyl radical composed by one, two or three rings, each one having 3-7 members and no more than three heteroatoms, fused or linked, optionally substituted or not substituted; c) aryl or heteroaryl radical composed by one, two or three rings, each one composed by 5-7 members and no more than three heteroatoms, optionally substituted or not substituted; d) arylalkyl radical composed by one, two or three aryl rings, where one or more substituents corresponds to alkyl C1-C5 with straight or branched chain optionally substituted or not substituted; e) heteroarylalkyl radical composed by one, two or three aryl or heteroaryl rings, each one having 5-7 members and no more than three heteroatoms, fused or linked, where any of the substituents corresponds to alkyl C1-C5 radical or heteroalkyl C1-C5 radical with straight or branched chain having no more than three heteroatoms, optionally substituted or not substituted; f) alkylcycloalkyl radical composed by one, two or three cycloalkyl radicals, each ring composed by 3-7 members, fused or linked where one or more substituents corresponds to alkyl C1-C5 with straight or branched chain optionally substituted or not substituted; g) heteroalkylcycloalkyl radical composed by one, two or three cycloalkyl or heterocycloalkyl rings, each ring composed by 3-7 members and no more than three heteroatoms, fused or linked where one or more substituents corresponds to C1-C5 alkyl or heteroalkyl groups with straight or branched chain having no more than three heteroatoms optionally substituted or not substituted; h) arylcycloalkyl radical composed by one, two or three aryl rings attached to one or more cycloalkyl radicals, each ring may have 3-7 members, optionally substituted or not substituted; i) heteroarylcycloalkyl radical composed by one, two or three aryl or heteroaryl rings, each ring composed by 5-7 members and no more than three heteroatoms, attached to one or more cycloalkyl or heterocycloalkyl rings, each one composed by 3-7 members and no more than three

heteroatoms, optionally substituted or not substituted; j) radical selected among the radicals: (a) – (i), where its substituents comprises one or more positive charged groups; k) radical selected among the radicals (a) – (i) where its substituents comprise one or more negative charged group,

(iii) **[C]** contains positive charged substituents and such substituents are selected among the following groups: RNH2, RNHR', RNR'R'', RC(NRR')=NR'', C(NR'R'')2=NR'''; RNHC(NR'R'') =NR'''; C(RNH)2=NR'; RC(R'NH)=NR'',

(iv) **[C]** contains negative charged substituents and such substituents are selected among the following: C(O)OH; S(O)OH; RR'P(O)(OH); R'OP(O)(OH); ROP(O)(OH)2; RP(O)(OH)2;(RO)2P(O)(OH); RS(O)2OH; ROS(O)2OH; tetrazole group, or,

(v) the head substructure **[C]** interacts with at least one of the following residues: a) residues forming the fusion peptide: Gly-100, Trp-101, Gly-102 and Phe-108, b) residues corresponding to the neighboring monomer in the dimeric structure of mature virions: Arg-2, Gly-5, Ile-6, Ser-7, Asn-8, His-27, Gly-28, Glu-44 and Asp-154, c) His-244 residue present in the "ij" loop, d) residues Ala-245 and Asp-98 belonging to the cavity associated to "ij" loop.

2- Use of chemical compounds according to claim 1 to attenuate or to inhibit the infection caused by a virus from the *flavivirus* genus, and such virus refers to any of the following viruses: Dengue virus type 1, Dengue virus type 2, Dengue virus type 3, Dengue virus type 4, West Nile virus, St Louis encephalitis virus, Japanese encephalitis virus, yellow fever virus, kunjin virus, Kyasanur Forest disease virus, Tick-born Encephalitis virus, Murray Valley virus, LANGAT virus, Louping disease virus and Powassan virus.

~~3- Use of chemical compounds according to claim 1, where such chemical compounds corresponds to any of the following: C-SIJ01001 up to C-SIJ01070, C-SIJ02071, C-SIJ03072 up to C-SIJ03076, C-SIJ04077 up to C-SIJ04084, C-SIJ05085, C-SIJ06086 up to C-SIJ06114, C-SIJ07115, C-SIJ08116, C-SIJ09117, C-SIJ10118 up to C-SIJ10120, C-SIJ11121 up to C-SIJ11139, C-SIJ012140 up to C-SIJ12149, C-SIJ013150 up to C-SIJ013156, C-SIJ14157 up to C-SIJ14159, C-SIJ15160 up to C-SIJ15165, C-SIJ17166 up to CSIJ17167, C-SIJ18168 up to C-SIJ18169, C-SIJ19170 up to C-SIJ19172, C-SIJ20173 up to C-SIJ20179, C-SIJ21180 up to C-SIJ21181, C-SIJ22182, C-SIJ23183, C-SIJ24184, C-SIJ25185, C-SIJ26186, C-SIJ27187, C-SIJ28188, C-SIJ29189, C-SIJ30190, C-SIJ31191, C-SIJ32192, C-SIJ33193, C-SIJ34194, CSIJ-35195, C-SIJ36196, C-SIJ37197 and C-SIJ38198.~~

~~4- Use of chemical compounds according to claim 3 where tautomers, geometric isomers, optically active forms such as enantiomers, diasterioisomers, racemic forms as well as pharmaceutically accepted salts of the chemical compounds described in the present invention are used.~~

~~5~~2- Use of chemical compounds for the preparation of a pharmaceutical composition for the prevention and/or the treatment of infections caused by Dengue virus ~~and other~~ *~~flavivirus~~* according to ~~the~~ claim~~s~~ 1~~, and 3~~.